Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COXEN Biomarker for Neoadjuvant Chemotherapy in Bladder Cancer
NCT02177695Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Aug 2014
- Primary completion
- Feb 2020
- Modality
- Targeted Liposomes, Orthosteric Ligands, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, Cisplatin micelle injection (HA132), methotrexate, vinblastine, pegylated liposomal doxorubicin in bladder cancer, sponsored by SWOG Cancer Research Network. Started Aug 2014; status: completed.
02
Drugs
gemcitabineCisplatin micelle injection (HA132)methotrexatevinblastinepegylated liposomal doxorubicin
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT02177695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02177695.